AAPL284.41+0.63 (+0.22%) ▲|ABBV251.15-2.21 (-0.87%) ▼|ABT93.54-0.58 (-0.62%) ▼|ACN129.55+0.57 (+0.44%) ▲|ADBE207.80+5.07 (+2.50%) ▲|AMAT658.51+31.67 (+5.05%) ▲|AMD526.32+4.74 (+0.91%) ▲|AMGN361.66+3.33 (+0.93%) ▲|AMT174.67-0.93 (-0.53%) ▼|AMZN240.66+7.97 (+3.43%) ▲|AVGO372.28+7.26 (+1.99%) ▲|AXP341.60+1.40 (+0.41%) ▲|BA218.56+1.38 (+0.63%) ▲|BAC58.13+0.32 (+0.54%) ▲|BKNG184.09+2.63 (+1.45%) ▲|BLK959.39-4.21 (-0.44%) ▼|BMY57.74+0.24 (+0.42%) ▲|BNY145.69+2.27 (+1.58%) ▲|BRK-B498.31+1.07 (+0.22%) ▲|C142.85+1.18 (+0.83%) ▲|CAT1,006.24+8.22 (+0.82%) ▲|CL92.23+0.17 (+0.18%) ▲|CMCSA25.49+2.32 (+9.99%) ▲|COF204.27+0.32 (+0.16%) ▲|COP105.80+0.10 (+0.09%) ▲|COST963.85+11.31 (+1.19%) ▲|CRM159.55+1.25 (+0.79%) ▲|CSCO116.65+2.88 (+2.53%) ▲|CVS103.67-0.65 (-0.62%) ▼|CVX170.72-0.19 (-0.11%) ▼|DE612.44-0.81 (-0.13%) ▼|DHR194.09-1.74 (-0.89%) ▼|DIS99.71+1.01 (+1.02%) ▲|DUK128.13-0.25 (-0.19%) ▼|EMR143.03-0.42 (-0.29%) ▼|FDX323.51+5.32 (+1.67%) ▲|GD349.37+2.66 (+0.77%) ▲|GE374.42+5.97 (+1.62%) ▲|GEV1,101.80+59.29 (+5.69%) ▲|GILD126.83-1.05 (-0.82%) ▼|GM77.91-0.18 (-0.23%) ▼|GOOG345.01+10.32 (+3.08%) ▲|GOOGL347.24+9.85 (+2.92%) ▲|GS1,035.93+16.32 (+1.60%) ▲|HD348.15-0.72 (-0.21%) ▼|HON248.86+5.45 (+2.24%) ▲|IBM271.02-0.61 (-0.22%) ▼|INTC124.03-4.30 (-3.35%) ▼|INTU275.49+7.77 (+2.90%) ▲|ISRG413.91+9.64 (+2.38%) ▲|JNJ254.70+0.04 (+0.02%) ▲|JPM330.35+1.30 (+0.39%) ▲|KO83.13+0.50 (+0.61%) ▲|LIN519.02-0.60 (-0.12%) ▼|LLY1,222.76+14.64 (+1.21%) ▲|LMT507.62+0.22 (+0.04%) ▲|LOW220.10-2.38 (-1.07%) ▼|LRCX389.88+10.79 (+2.85%) ▲|MA508.72+9.70 (+1.94%) ▲|MCD269.90+0.14 (+0.05%) ▲|MDLZ60.70-0.09 (-0.15%) ▼|MDT81.20+0.22 (+0.27%) ▲|META568.16+17.91 (+3.25%) ▲|MMM165.10+1.09 (+0.66%) ▲|MO73.65-0.14 (-0.19%) ▼|MRK128.07-0.59 (-0.46%) ▼|MS215.20+3.17 (+1.50%) ▲|MSFT379.04+6.07 (+1.63%) ▲|MU1,086.02-46.32 (-4.09%) ▼|NEE88.09-0.48 (-0.54%) ▼|NFLX75.47+1.66 (+2.25%) ▲|NKE41.13+0.38 (+0.92%) ▲|NOW101.84+3.50 (+3.56%) ▲|NVDA195.11+2.58 (+1.34%) ▲|ORCL152.60+4.07 (+2.74%) ▲|PEP140.79-0.60 (-0.42%) ▼|PFE24.35+0.06 (+0.23%) ▲|PG147.81-1.21 (-0.81%) ▼|PLTR118.08+5.15 (+4.56%) ▲|PM179.97-0.81 (-0.45%) ▼|QCOM190.75+1.36 (+0.72%) ▲|RTX188.95+0.96 (+0.51%) ▲|SBUX104.63+0.03 (+0.03%) ▲|SCHW91.02+0.35 (+0.38%) ▲|SO96.95-0.21 (-0.22%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.67-1.06 (-4.64%) ▼|TMO505.55-7.48 (-1.46%) ▼|TMUS175.99-6.69 (-3.66%) ▼|TSLA392.61+12.90 (+3.40%) ▲|TXN287.05+1.62 (+0.57%) ▲|UBER77.48+1.28 (+1.68%) ▲|UNH420.45-7.45 (-1.74%) ▼|UNP271.08+2.73 (+1.02%) ▲|UPS107.75-0.40 (-0.37%) ▼|USB61.07+0.16 (+0.26%) ▲|V342.34+6.11 (+1.82%) ▲|VZ44.07-2.48 (-5.32%) ▼|WFC84.07+0.21 (+0.25%) ▲|WMT116.13+0.44 (+0.38%) ▲|XOM136.37-0.18 (-0.13%) ▼|AAPL284.41+0.63 (+0.22%) ▲|ABBV251.15-2.21 (-0.87%) ▼|ABT93.54-0.58 (-0.62%) ▼|ACN129.55+0.57 (+0.44%) ▲|ADBE207.80+5.07 (+2.50%) ▲|AMAT658.51+31.67 (+5.05%) ▲|AMD526.32+4.74 (+0.91%) ▲|AMGN361.66+3.33 (+0.93%) ▲|AMT174.67-0.93 (-0.53%) ▼|AMZN240.66+7.97 (+3.43%) ▲|AVGO372.28+7.26 (+1.99%) ▲|AXP341.60+1.40 (+0.41%) ▲|BA218.56+1.38 (+0.63%) ▲|BAC58.13+0.32 (+0.54%) ▲|BKNG184.09+2.63 (+1.45%) ▲|BLK959.39-4.21 (-0.44%) ▼|BMY57.74+0.24 (+0.42%) ▲|BNY145.69+2.27 (+1.58%) ▲|BRK-B498.31+1.07 (+0.22%) ▲|C142.85+1.18 (+0.83%) ▲|CAT1,006.24+8.22 (+0.82%) ▲|CL92.23+0.17 (+0.18%) ▲|CMCSA25.49+2.32 (+9.99%) ▲|COF204.27+0.32 (+0.16%) ▲|COP105.80+0.10 (+0.09%) ▲|COST963.85+11.31 (+1.19%) ▲|CRM159.55+1.25 (+0.79%) ▲|CSCO116.65+2.88 (+2.53%) ▲|CVS103.67-0.65 (-0.62%) ▼|CVX170.72-0.19 (-0.11%) ▼|DE612.44-0.81 (-0.13%) ▼|DHR194.09-1.74 (-0.89%) ▼|DIS99.71+1.01 (+1.02%) ▲|DUK128.13-0.25 (-0.19%) ▼|EMR143.03-0.42 (-0.29%) ▼|FDX323.51+5.32 (+1.67%) ▲|GD349.37+2.66 (+0.77%) ▲|GE374.42+5.97 (+1.62%) ▲|GEV1,101.80+59.29 (+5.69%) ▲|GILD126.83-1.05 (-0.82%) ▼|GM77.91-0.18 (-0.23%) ▼|GOOG345.01+10.32 (+3.08%) ▲|GOOGL347.24+9.85 (+2.92%) ▲|GS1,035.93+16.32 (+1.60%) ▲|HD348.15-0.72 (-0.21%) ▼|HON248.86+5.45 (+2.24%) ▲|IBM271.02-0.61 (-0.22%) ▼|INTC124.03-4.30 (-3.35%) ▼|INTU275.49+7.77 (+2.90%) ▲|ISRG413.91+9.64 (+2.38%) ▲|JNJ254.70+0.04 (+0.02%) ▲|JPM330.35+1.30 (+0.39%) ▲|KO83.13+0.50 (+0.61%) ▲|LIN519.02-0.60 (-0.12%) ▼|LLY1,222.76+14.64 (+1.21%) ▲|LMT507.62+0.22 (+0.04%) ▲|LOW220.10-2.38 (-1.07%) ▼|LRCX389.88+10.79 (+2.85%) ▲|MA508.72+9.70 (+1.94%) ▲|MCD269.90+0.14 (+0.05%) ▲|MDLZ60.70-0.09 (-0.15%) ▼|MDT81.20+0.22 (+0.27%) ▲|META568.16+17.91 (+3.25%) ▲|MMM165.10+1.09 (+0.66%) ▲|MO73.65-0.14 (-0.19%) ▼|MRK128.07-0.59 (-0.46%) ▼|MS215.20+3.17 (+1.50%) ▲|MSFT379.04+6.07 (+1.63%) ▲|MU1,086.02-46.32 (-4.09%) ▼|NEE88.09-0.48 (-0.54%) ▼|NFLX75.47+1.66 (+2.25%) ▲|NKE41.13+0.38 (+0.92%) ▲|NOW101.84+3.50 (+3.56%) ▲|NVDA195.11+2.58 (+1.34%) ▲|ORCL152.60+4.07 (+2.74%) ▲|PEP140.79-0.60 (-0.42%) ▼|PFE24.35+0.06 (+0.23%) ▲|PG147.81-1.21 (-0.81%) ▼|PLTR118.08+5.15 (+4.56%) ▲|PM179.97-0.81 (-0.45%) ▼|QCOM190.75+1.36 (+0.72%) ▲|RTX188.95+0.96 (+0.51%) ▲|SBUX104.63+0.03 (+0.03%) ▲|SCHW91.02+0.35 (+0.38%) ▲|SO96.95-0.21 (-0.22%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.67-1.06 (-4.64%) ▼|TMO505.55-7.48 (-1.46%) ▼|TMUS175.99-6.69 (-3.66%) ▼|TSLA392.61+12.90 (+3.40%) ▲|TXN287.05+1.62 (+0.57%) ▲|UBER77.48+1.28 (+1.68%) ▲|UNH420.45-7.45 (-1.74%) ▼|UNP271.08+2.73 (+1.02%) ▲|UPS107.75-0.40 (-0.37%) ▼|USB61.07+0.16 (+0.26%) ▲|V342.34+6.11 (+1.82%) ▲|VZ44.07-2.48 (-5.32%) ▼|WFC84.07+0.21 (+0.25%) ▲|WMT116.13+0.44 (+0.38%) ▲|XOM136.37-0.18 (-0.13%) ▼|
27.6 C
New York
Monday, June 29, 2026

Tag: cross

newssourceFORcompanyinformationcontent1releasesmarket

“Global Connectivity • Industry Interaction” International Sports Industry Salon Held in Hong Kong

CHENGDU, China, June 20, 2025 /PRNewswire/ -- On June 20, the "Global Connectivity • Industrial Interaction" International Sports Industry Salon was held in Hong...

CROSS TIMBERS ROYALTY TRUST DECLARES JUNE CASH DISTRIBUTION

DALLAS, June 20, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

1000 MIGLIA 2025, today the leg that will unite the Adriatic and Tyrrhenian seas

Departing early in the morning from Cervia, the crews will stop in Pontedera for lunch. Following this, entry into the Naval Academy in Livorno will complete the crossing of Italy from east to west 
Departing early in the morning from Cervia, the crews will stop in Pontedera for lunch. Following this, entry into the Naval Academy in Livorno will complete the crossing of Italy from east to west

castLabs delivers new React Native player SDK to expand 3SS’ 3Ready solution for Proximus

BERLIN, June 20, 2025 /PRNewswire/ -- castLabs, a global pioneer in premium digital video technology, and 3 Screen Solutions (3SS), leading provider of software...

Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology

BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd....

Gate Releases May 2025 Transparency Report: Brand Revamp Ignites Strategic Acceleration

PANAMA CITY, June 20, 2025 (GLOBE NEWSWIRE) -- Gate, a global leader in cryptocurrency trading, has released its May 2025 Transparency Report, revealing remarkable growth across key business indicators. Amid improving market sentiment and a maturing regulatory landscape, the platform recorded historic highs in trading volume and user activity, accelerated brand globalization efforts, advanced compliance achievements, and further expanded its Web3 ecosystem.

GVG Takes Legal Action Through Carter-Ruck to Counter Alleged Disinformation Campaigns

GVG has instructed leading London law firm Carter-Ruck to formally address articles published by Commsrisk. LONDON, June 20, 2025 /PRNewswire/ -- Global Voice Group (GVG), a pioneer...

LPS and QAX Announce Strategic Partnership for Cybersecurity, Unveiling Security Operation Centre and End-to-End Security Services

The duo's first joint Security Operation Centre (SOC) in Hong Kong addresses the urgent need for advanced cybersecurity defenses amidst surging cyber threats.The new SOC...

EMA Confluence Validates Trend Continuation Setup

OverviewThe Multiple EMA Trend Confirmation Trading System is rooted in technical analysis, leveraging Exponential Moving Averages (EMAs) and multi-timeframe charts to identify trend direction...

eBay and Vestiaire Beg for Tariff Mercy

Last month, Suzanne Smith-Darley thought she snagged a deal on a used Chanel bag from Japan for $800 on eBay. Then, DHL slapped her...

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

Biological Safety Cabinets Market to Reach USD 448.4 Million by 2032, Driven by Rising Biosafety Standards and Research Demand

PUNE, India, June 19, 2025 /PRNewswire/ -- According to a recent market analysis published by Credence Research Inc., the global Biological Safety Cabinets (BSCs) market...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 
First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCross

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers